Short Interest in Alpha Tau Medical Ltd. (NASDAQ:DRTSW) Decreases By 46.4%

Alpha Tau Medical Ltd. (NASDAQ:DRTSW) was the target of a large decline in short interest in March. As of March 15th, there was short interest totalling 3,000 shares, a decline of 46.4% from the February 29th total of 5,600 shares. Based on an average daily trading volume, of 8,100 shares, the short-interest ratio is presently 0.4 days.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Walleye Capital LLC grew its position in Alpha Tau Medical by 10.9% in the second quarter. Walleye Capital LLC now owns 204,285 shares of the company’s stock worth $98,000 after acquiring an additional 20,096 shares in the last quarter. Chicago Partners Investment Group LLC bought a new stake in Alpha Tau Medical in the first quarter worth $55,000. Walleye Trading LLC bought a new stake in Alpha Tau Medical in the first quarter worth $65,000. Jane Street Group LLC bought a new position in shares of Alpha Tau Medical during the first quarter valued at about $64,000. Finally, Polar Asset Management Partners Inc. bought a new position in shares of Alpha Tau Medical during the first quarter valued at about $134,000.

Alpha Tau Medical Stock Down 4.9 %

Alpha Tau Medical stock traded down $0.01 during mid-day trading on Thursday, reaching $0.25. The company’s stock had a trading volume of 850 shares, compared to its average volume of 7,312. Alpha Tau Medical has a 12-month low of $0.14 and a 12-month high of $0.45. The firm’s fifty day moving average price is $0.27 and its two-hundred day moving average price is $0.26.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.